Physician profile
Jonathan Doty
NPI 1205495975
$30,582.07
in general payments reported to CMS, 2019-2025
26 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2021: $235 · 2022: $114 · 2023: $713 · 2024: $16K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $11K · Travel and Lodging: $3,443 · Food and Beverage: $3,353 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,352.00 |
| Consulting Fee | $10,733.25 |
| Travel and Lodging | $3,443.13 |
| Food and Beverage | $3,353.40 |
| Education | $113.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16,723.20 | 2021-2025 | |
| Tg Therapeutics, INC. | $6,697.98 | 2023-2025 | |
| Genentech USA, INC. | $4,950.91 | 2019-2025 | Ocrevus, Enspryng |
| Emd Serono, INC. | $515.70 | 2023-2025 | Mavenclad |
| Horizon Therapeutics Plc | $269.13 | 2023 | Uplizna |
| Biogen, INC. | $249.72 | 2023-2025 | Tysabri, Tysabri, Spinraza |
| E.R. Squibb & Sons, L.L.C. | $224.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $170.08 | 2025 | |
| Amgen INC. | $118.04 | 2024 | Uplizna |
| Mdd US Operations, LLC | $112.02 | 2019 | |
| Lilly USA, LLC | $60.25 | 2024 | Emgality, Amyvid, Reyvow |
| Sumitomo Pharma America, INC. | $59.29 | 2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $56.70 | 2024 | Soliris |
| Abbvie INC. | $55.04 | 2023-2024 | Ubrelvy, Botox |
| Celgene Corporation | $48.47 | 2023-2024 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $44.09 | 2024 | |
| Lundbeck LLC | $38.54 | 2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $36.43 | 2023-2024 | Ztlido |
| Csl Behring | $24.07 | 2024 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $23.72 | 2023 | |
| Octapharma USA, INC. | $20.04 | 2024 | Panzyga |
| Pfizer INC. | $17.98 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.93 | 2023 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.69 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $15.48 | 2024 | |
| Urogen Pharma, INC. | $15.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.